Oxbridge Re Holdings Limited announced that CEO Jay Madhu will speak at Uncorrelated Cayman 2026 about their success in issuing tokenized reinsurance securities through SurancePlus and plans to expand into third-party reinsurance and AI data center financing with AI GridWorks. The company reported strong returns on previous tokenized reinsurance offerings and is leveraging blockchain technology to broaden investor access. This move highlights Oxbridge's innovative approach to combining digital finance with AI infrastructure, aiming to open new investment opportunities in AI data centers.
Oxbridge and SurancePlus are featured in this context of financial innovation, with Pluang's Financials sector showing varied performance as of Nov 02, 2026 21:03 WIB. Among 142 US financial stocks, 88 rose while 25 fell. Notably, RIOT at USD 13.07 and CLSK at USD 7.81 both gained just over 2%, contrasting with SAN at USD 11.42 which rose by 1.92%, with hold times ranging from 18 to 56 days on Pluang.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
